Investing Center Preview – Manage your investments and watch your net worth grow.
LLY:NYSE – Large Cap Stock (Drug Manufacturers)
Eli Lilly and Co – LLY Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
819.36 | 7.33 (+0.90%) | 677.09 - 972.53 | 2.8 million |
Market data as of 4:00PM 06/13/25. Quotes are delayed by at least 15 min.
Overview - LLY
Open | 810.34 |
---|---|
Previous Close | 812.03 |
Day's Range | 808.10 - 825.00 |
Market Cap | 776.5B |
Avg Volume (10 Day) | 3.0M |
Price/Earnings (Trailing 12 Mo.) | 66.7x |
Earnings Per Share (Trailing 12 Mo.) | 3.053 |
Dividend Yield | 1.50 (0.73%) |
One-Click Scorecard - LLY


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Fail |
---|---|
Avoids excess debt? | Fail |
Converting sales to profits? | Fail |
Shareholder's money handled rationally? | Pass |
Increased shareholder value? | Fail |
Consistently increased owner earnings? | Pass |
Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Pass |
---|---|
Room to increase dividends? | Fail |
Increased earnings over time? | Pass |
Borrows within reasonable limits? | Fail |
Stock is undervalued? | Fail |
Have investors caught on? | Fail |
Has support of institutional investors? | Pass |
Has sufficient liquidity? | Pass |
Latest Headlines - LLY
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
PR Newswire - Monday 06/02/2025 10:00 AM ET
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
PR Newswire - Monday 06/02/2025 8:00 AM ET
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
PR Newswire - Thursday 05/29/2025 5:00 PM ET
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
PR Newswire - Tuesday 05/27/2025 10:00 AM ET
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Thursday 05/22/2025 5:05 PM ET
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
PR Newswire - Wednesday 05/21/2025 4:21 PM ET
Industry Position - LLY
LLY | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 32.00% | |
Net Income Growth (1yr) | 102.08% | |
Total Debt/Equity | 2.44 | |
LT Debt/Equity | 2.19 | |
Earnings Yield | 1.50% | |
Price/Sales | 15.10 |
Competitors - LLY
Company | Last | Change |
---|---|---|
1561.00 | -1.14% | |
3284.90 | -0.94% | |
1689.50 | -0.82% | |
28050.00 | -0.71% | |
Johnson & Johnson | 157.10 | +0.28% |
Data is delayed by at least 15 min.